Clinical significance of serum mitochondrial DNA in lung cancer

Clinical Biochemistry

Volumn 46, Issue 15, 2013, Pages 1474-1477

  Hou, Yu Lei ^a   Chen, Juan Juan ^a   Wu, Yan Feng ^a   Xue, Cheng Jun ^a   Li, Feng Zeng ^a   Zheng, Qian ^a   Chen, Hui ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Diagnostic efficacy; Lung cancer; Serum mitochondrial DNA

Indexed keywords

MITOCHONDRIAL DNA;

ADULT; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG DISEASE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME FLUORESCENT QUANTITATIVE POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

DIAGNOSTIC EFFICACY; LUNG CANCER; SERUM MITOCHONDRIAL DNA;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA COPY NUMBER VARIATIONS; DNA, MITOCHONDRIAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84884353448     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.04.009     Document Type: Article

References (22)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
3. Yang L., Ruan W.J., Chen E.G., Ying K.J. Diagnosis value of serum NKX2-1 for primary lung cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban 2012, 41:535-539.
4. Higqins G., Roper K.M., Waston I.J., Blackhall F.H., Rom W.N., Pass H.I., et al. Variant Ciz1 is a circulating biomarker for early-stage lung cancer. Proc Natl Acad Sci U S A 2012, 109:3128-3135.
5. Mandel P., Metais P. Les acids nucleiques du plasma sanguine chezl'homme. CR Acad Sci paris. 1948, 142:241-243.
6. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
7. Elliger J., Muller S.C., Stadler T.C., Jung A., Von Ruecker A., Bastian P.J., et al. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 2011, 29:124-129.
8. Mehra N., Penning M., Mass J., Van Daal N., Giles R.H., Voest E.E., et al. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res 2007, 13:421-426.
9. Zachariah R.R., Schmid S., Buerki N., Radpour R., Holzgreve W., Zhong X. Levels of cell-free circulating nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol 2008, 112:843-850.
10. Ellinger J., Albers P., Muller S.C., Von Ruecker A., Bastian P.J. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. BJU Int 2009, 104:48-52.
11. Kohler C., Radpour R., Barekati Z., Asadollahi R., Bitzer J., Wight E., et al. Levels of circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 2009, 8:105.
12. Uzawa K., Baba T., Uchida F., Yamatoji M., Kasamatsu A., Sakamoto Y., et al. Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squmous carcinoma. Oncotarget 2012, 3:670-677.
13. Wang H.M., Dai J. Changes on mitochondrial DNA content in non-small-cell-lung-cancer. Zhongguo Fei Ai Za Zhi 2011, 14:141-145.
14. Travis W.D., Brambilla E., Mueller-Hermelink H.K., Harris C.C. World health organization classification tumors of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
15. Ellinger J., Müller D.C., Müller S.C., Hauser S., Heukamp L.C., Von Ruecker A., et al. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol 2012, 30:509-515.
16. Wu T.L., Zhang D., Chia J.H., Tsao K.H., Sun C.F., Wu J.T. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002, 321:77-87.
17. Ellinger J., Bastian P.J., Hann K.l., Heukamp L.C., Buettner R., Fimmers R., et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients with qualify as diagnostic and prognostic indicators. Int J Cancer 2008, 122:138-143.
18. Ellinger J., Muller S.C., Wernert N., Von Ruecker A., Bastian P.J. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence following prostatectomy. BUJU Int 2008, 102:628-632.
19. Hosgood H.D., Liu C.S., Rothman N., Weinstein S.J., Bonner M.R., Shen M., et al. Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. Carcinogenesis 2010, 31:847-849.
20. Yu M., Wan Y.F., Zou Q.H. Cell-free circulating mitochondrial DNA in serum: a potential non-invasive biomarker for Ewing's sarcoma. Arch Med Res 2012, 43:389-394.
21. Xia P., An H.X., Dang C.X., Radpour R., Kohler C., Fokas E., et al. Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer 2009, 9:454.
22. Chu X.Y., Hou X.B., Song W.A., Xue Z.Q., Wang B., Zhang L.B. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer patients with suspicious pulmonary masses. Cancer Biol Ther 2011, 11(12):995-1000.